Pfizer Inc. (PFE.US) applies for market approval in China for oral preventive medication for migraine headaches.
On March 31, the CDE website showed that Pfizer's Sumatriptan Succinate Orally Disintegrating Tablets have applied for a new indication in China, for the preventive treatment of adult episodic migraine.
On March 31st, the CDE website showed that Pfizer Inc.'s (PFE.US) rimegepant sulfate orally disintegrating tablets have applied for a new indication in China, for the preventive treatment of episodic migraine in adults.
Rimegepant is the world's first and only calcitonin gene-related peptide (CGRP) receptor antagonist using patented orally disintegrating tablet technology. It was first approved by the FDA for acute treatment of adult acute migraine in February 2020. In May 2021, rimegepant expanded its indications in the United States for the prevention of adult episodic migraine. In January 2024, the drug was approved for the first time in China. According to Pfizer Inc.'s financial report, global sales of rimegepant in 2025 were $1.424 billion.
Related Articles
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
On March 31st, MNSO (09896) spent 396,900 USD to repurchase 98,100 shares.
In 2026, the new NIO 5566 model will be launched, and the Hong Kong stock market closed at noon skyrocketed by over 9%.
Poly Property (00119) 2025 Annual Report: Continuous optimization of structure, sales among top fifteen
On March 31st, MNSO (09896) spent 396,900 USD to repurchase 98,100 shares.
